Cardiac Inflammation
Conditions
Brief summary
Gallium-68-DOTATOC binds primarily with high affinity to somatostatin subtype 2 (SSTR2) receptors and these somatostatin receptors are also overexpressed on inflammation cells when activated. The hypothesis is that the GATED mode on a Gallium-68-DOTATOC cardiac recording would be able to highlight abnormalities that could be correlated with the age of the patients and their cardiovascular risk factors.
Detailed description
People with the selection criteria for the study, coming to the nuclear medicine department in order to benefit from a Gallium-68-DOTATOC PET/CT exam as part of a diagnostic or pre-therapeutic assessment of a neuroendocrine tumor will be offer to participate in the study After sign consent, patients were install in a room to have blood drawn for Troponin Ic, BNP and CRP and after Gallium-68-DOTATOC infusion Gallium-68-DOTATOC PET/CT will be recorded and immediately the cardiac record in Gated mode
Interventions
OTHERCardiac ECG-gated PET imaging will added
Blood sample will be used to measure troponin, BNP and CRP . After 68Ga-DOTATOC PET/CT whole body recording, a cardiac ECG-gated PET imaging will added
Sponsors
Central Hospital, Nancy, France
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Persons who have received complete information on the organization of the research and who have signed the informed consent and: * Age ≥ 18 years old. * Having read and understood the information document. * Affiliated to a social security scheme. Person for whom a 68Ga-DOTATOC PET/CT exam is requested as part of the diagnostic or pre-therapeutic assessment of a neuroendocrine tumour.
Exclusion criteria
Person with * Hypersensitivity during previous use of 68Ga-DOTATOC * Impossibility of performing a PET-CT (patient agitated, confused, etc.). * History of heart disease, * Severe arrhythmia that does not allow the PET synchronized with the ECG * Severe renal insufficiency (GFR \<30 ml/min/1.73 m2) * Treated with a somatostatin analogue. * Cushing's syndrome * Pregnant woman, likely to be or breastfeeding * Adult subject to a legal protection measure (guardianship, curators, legal safeguard) * Person of legal age unable to express their consent * Person deprived of liberty by a judicial or administrative decision * Person, subject to psychiatric care under articles L. 3212-1 and L. 3213-1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relationship between the captation of radiotracer and the cardiovascular disease | 1 day | Measurement of myocardial activity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relationship between the captation of radiotracer and the troponin value | 1 day | Correlation between the myocardial activity and the troponin value |
Countries
France
Contacts
CONTACTVERONIQUE ROCH, MSc
PRINCIPAL_INVESTIGATORMathieu PERRIN, MD
CHRU Nancy
Outcome results
None listed